FDA COVID-19 Diagnostic Test Fellowship
*Applications will be reviewed on a rolling-basis.
A research opportunity is currently available in the laboratory of Dr. Paul Carlson in the Office of Vaccine Research and Review (OVRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
Since SARS-CoV-2 has been detected in the stool of both symptomatic and asymptomatic individuals, a better understanding of stool shedding and methods for testing for the virus in stool is vital to ensure the continued safety of Fecal Microbiota Transplantation (FMT) products. Under the guidance of a mentor, the selected participant will be involved in the development and validation of assays for testing stool for SARS-CoV-2, including qPCR, ddPCR, NGS, and CRISPR methodologies. These methods will also be applied by the participant for development of diagnostic tests for malaria in collaboration with Dr. Heather Painter (FDA/CBER).
Anticipated Appointment Start Date: July 1, 2020
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Qualifications
The qualified candidate should be currently pursuing or have received a bachelor's, master's or doctoral degree in one of the relevant fields. Degree must have been received within five years of the appointment start date.
This opportunity is available to US citizens only.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity (FDA-CBER-2020-0052) in your email.